Journal of Pharmaceutical Negative Results

ORIGINAL ARTICLE
Year
: 2015  |  Volume : 6  |  Issue : 1  |  Page : 2--6

Nonprotective role of losartan in cisplatin-induced nephrotoxicity in ovariectomized rat model treated with estradiol


Fereshteh Ghadirian1, Mehdi Nematbakhsh2, Shahla Roozbehani3, Safoora Mazaheri4, Ardeshir Talebi5, Zahra Pezeshki4, Farzaneh Ashrafi6 
1 Water and Electrolytes Research Center; Department of Biology, Falavarjan Branch, Islamic Azad University, Iran
2 Water and Electrolytes Research Center; Department of Physiology, University of Medical Sciences; Isfahan MN Institute of Basic and Applied Sciences Research, Isfahan, Iran
3 Department of Biology, Falavarjan Branch, Islamic Azad University, Isfahan, Iran
4 Water and Electrolytes Research Center, University of Medical Sciences, Isfahan, Iran
5 Department of Clinical Pathology, University of Medical Sciences, Isfahan, Iran
6 Department of Internal Medicine, University of Medical Sciences, Isfahan, Iran

Correspondence Address:
Mehdi Nematbakhsh
Department of Physiology, Water and Electrolytes Research Center, Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan
Iran

Objective: The aim was to study the role of losartan on cisplatin (CP)-induced nephrotoxicity in an estradiol replacement rat model. Materials and Methods: Forty-seven female Wistar rats were ovariectomized and divided into seven groups. Groups 1 and 2 were treated with placebo (sesame oil) on a weekly basis for 4 weeks, and then they received saline or CP (2.5 mg/kg/day) for the next 7 days, respectively. Group 3 received estradiol (250 μg/kg/week) for 4 weeks, and then treated with losartan (10 mg/kg/day) for the next 10 days while from day 3; they also received CP for 7 days. Group 4 had treatment regimen the same as Group 3, except saline instead of losartan. Groups 5 and 6 were treated similar to Groups 3 and 4, respectively, but the dose of estradiol was doubled. Finally, Group 7 was treated as Group 3 except vehicle instead of estradiol. At the end of the experiment, blood samples were obtained to measure blood urea nitrogen (BUN), creatinine (Cr), nitric oxide metabolite (nitrite) and malondialdehyde (MDA). The kidney tissues were also subjected to pathology investigations. Results: Cisplatin significantly increased the serum level of BUN, Cr, and MDA (P < 0.05). CP also increased kidney weight (KW) and kidney tissue damage score (KTDS), and decreased bodyweight significantly (P < 0.05). There is a significant difference in KTDS, weight changes and serum level of MDA between positive control groups compared with the groups received combination of losartan and CP (P < 0.05). Conclusions: It seems that the estrogen could promote CP-induced nephrotoxicity. Losartan also did not intensify CP-induced nephrotoxicity. Accordingly, supplementation of losartan to attenuate CP-induced nephrotoxicity in ovariectomized model treated with estradiol is not suggested.


How to cite this article:
Ghadirian F, Nematbakhsh M, Roozbehani S, Mazaheri S, Talebi A, Pezeshki Z, Ashrafi F. Nonprotective role of losartan in cisplatin-induced nephrotoxicity in ovariectomized rat model treated with estradiol.J Pharm Negative Results 2015;6:2-6


How to cite this URL:
Ghadirian F, Nematbakhsh M, Roozbehani S, Mazaheri S, Talebi A, Pezeshki Z, Ashrafi F. Nonprotective role of losartan in cisplatin-induced nephrotoxicity in ovariectomized rat model treated with estradiol. J Pharm Negative Results [serial online] 2015 [cited 2020 May 26 ];6:2-6
Available from: http://www.pnrjournal.com/article.asp?issn=0976-9234;year=2015;volume=6;issue=1;spage=2;epage=6;aulast=Ghadirian;type=0